Simbolo M et al. [9] revealed BAP1 mutations in 10 out of 70 ICC cases (14.3%) and 1 out of 26 cases (3.8%) of gallbladder carcinoma (GBC), whereas Jiao.Y et al. [8] revealed mutations in 8 out of 32 ICC cases (25%; discovery screen) and 1 out of 8 GBC cases (13%). This evidence concerns the gene BAP1 and intrahepatic cholangiocarcinoma.